Long-term treatment in arterial hypertension for protecting hypertrophic myocardium

1991 ◽  
pp. 223-233
Author(s):  
Martin Vogt ◽  
W. Motz ◽  
B. E. Strauer
Keyword(s):  
Arterial Hypertension ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Hypertrophic Myocardium

INFLUENCE OF THIAZIDES ON THYROID PARAMETERS IN MAN

1978 ◽  
Vol 89 (4) ◽  
pp. 673-678 ◽  
Author(s):  
Karine Bech ◽  
Lis Skovsted ◽  
Kaj Siersbæk-Nielsen ◽  
Jens Mølholm Hansen
Keyword(s):  
Arterial Hypertension ◽  
Urinary Iodine ◽  
Iodine Intake ◽  
Term Treatment ◽  
Distribution Volume ◽  
Long Term Treatment ◽  
Thyroid Uptake ◽  
Iodine Metabolism ◽  
Normal Controls

ABSTRACT Iodine metabolism and thyroid hormones in blood were studied in 19 men and 11 women who had been treated with thiazides for arterial hypertension from 1 month to 15 years. The results were compared with the findings from age-matched normal controls. No differences were found regarding 24-h 131I-thyroid uptake, thyroid iodide clearance, renal iodide clearance, plasma inorganic iodide, absolute iodine uptake (AIU), serum thyroxine (T4 (D)), resin T3 test (T3U) and TSH after TRH. Twenty-four-hour urinary iodine was higher in the patients treated with diuretics which could be explained by increased iodine intake. The findings of increased serum triiodothyronine (T3 (RIA)) and reverse T3 (rT3) might be due to changes in distribution volume in the thiazide-treated patients. Long-term treatment with thiazides in man do not lead to iodine depletion.

scholarly journals Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension

2016 ◽  
Vol 311 (4) ◽  
pp. R721-R726 ◽  
Author(s):  
Martine Clozel
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Structural Changes ◽  
Term Treatment ◽  
Vasopressin Release ◽  
Long Term Treatment ◽  
Pulmonary Arterial ◽  
Kinetics Of

Endothelin receptor antagonists (ERAs) are used for the treatment of pulmonary arterial hypertension (PAH). Macitentan, a dual (ETA+ETB) ERA approved for the long-term treatment of PAH, was discovered through a tailored research program aimed at improving efficacy and safety over the existing ERAs. The goal of improved efficacy was based on the understanding that not only the ETA receptor but also the ETB receptor contributed to the hemodynamic and structural changes induced by endothelin-1 (ET-1) in pathological conditions and on the predefined requirements for optimal tissue penetration and binding kinetics of the antagonist. The goal of improved safety was based on the discovery of the role of ETB receptors in vascular permeability and vasopressin release and on the elucidation of the mechanism by which bosentan (the first approved oral dual ETA/ETB ERA) caused liver enzyme changes. Our intention was to design a molecule that would block ETA and ETB receptors optimally and would not interfere with bile salt elimination. This review takes us through the drug discovery journey that led to the discovery, development, and registration of macitentan.

scholarly journals Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension

Circulation ◽  
2003 ◽  
Vol 108 (17) ◽  
pp. 2066-2069 ◽  
Author(s):  
Evangelos D. Michelakis ◽  
Wayne Tymchak ◽  
Michelle Noga ◽  
Linda Webster ◽  
Xi-Chen Wu ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Functional Capacity ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Pulmonary Arterial

Long-term Treatment With Oral Sildenafil in Addition to Continuous IV Epoprostenol in Patients With Pulmonary Arterial Hypertension

CHEST Journal ◽  
2003 ◽  
Vol 123 (4) ◽  
pp. 1293-1295 ◽  
Author(s):  
Leopold Stiebellehner ◽  
Ventzislav Petkov ◽  
Karin Vonbank ◽  
Georg Funk ◽  
Peter Schenk ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Pulmonary Arterial

scholarly journals Long-term indapamide retard therapy in adolescents with Stage I arterial hypertension

2011 ◽  
Vol 10 (2) ◽  
pp. 6-12
Author(s):  
I. V. Logacheva ◽  
E. A. Gunicheva
Keyword(s):  
Endothelial Dysfunction ◽  
Arterial Hypertension ◽  
Reactive Hyperemia ◽  
Intima Media Thickness ◽  
Term Treatment ◽  
Stage I ◽  
Control Group ◽  
Large Artery ◽  
Long Term Treatment

Aim. To study the dynamics of office blood pressure (BP) levels, autonomic balance, endothelial dysfunction, and vascular remodelling in adolescents with Stage I arterial hypertension (AH), treated with indapamide retard (IR). Material and methods. In total, the study included 41 adolescent boys, aged 16-18 years, with Stage I AH (main group, MG), and 27 healthy adolescents (control group, CG). The MG participants received, IR (1,5 mg/day) for 6 months. At baseline and in the end of the study, all participants underwent office BP measurement, echocardiography, veloergometry, and the assessment of heart rate variability (HRV), endothelial dysfunction (reactive hyperemia test, endotelin-1 levels), microalbuminuria (MAU), and vascular parameters, such as large artery rigidity and intima-media thickness. Results. Target BP levels were achieved in all MG patients by Week 4 of the treatment, with normal BP values registered throughout the follow-up period. Indapamide therapy was associated with decreased hemodynamic cardiovascular load, normalized endothelial function, and MAU disappearance. IR monotherapy had beneficial effects on HRV, due to moderate parasympathetic stimulation. Conclusion. IR is an effective and safe medication for long-term treatment of adolescents with Stage I AH.

Changes in Glomerular Filtration Rate during Long-Term Treatment with Propranolol in Patients with Arterial Hypertension

1973 ◽  
Vol 44 (2) ◽  
pp. 129-134 ◽  
Author(s):  
H. Ibsen ◽  
P. Sederberg-Olsen
Keyword(s):  
Blood Flow ◽  
Glomerular Filtration Rate ◽  
Arterial Hypertension ◽  
Glomerular Filtration ◽  
Filtration Rate ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Order Of Magnitude ◽  
51Cr Edta

1. Glomerular filtration rate was determined from 51Cr—EDTA clearance in twenty hypertensive subjects treated with propranolol. 2. A significant mean decrease of 13% in the glomerular filtration rate was found during treatment, and an increase of the same order of magnitude after withdrawal of propranolol. 3. It is suggested that these changes are related to a reduction in the renal blood flow. 4. No significant changes were found in plasma volume.

Sign in / Sign up

Export Citation Format

Share Document